News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Johnson & Johnson (JNJ), Pharmacyclics, Inc. (PCYC)'s Closely Watched Leukemia Drug Effective In Long Term Study


12/9/2013 6:43:06 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A closely watched leukemia drug developed by Johnson & Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting. The oral drug, ibrutinib, last month won U.S. approval to treat a rare and aggressive form of non-Hodgkin lymphoma known as mantle cell lymphoma. It is awaiting a Food and Drug Administration decision on treating chronic lymphocytic leukemia (CLL), a slowly progressing form of blood cancer that primarily affects people aged 65 and older.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
   
Leukemia

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES